|
Encode
® Research Project
Sickle Cell & Thalassemia
|
NUTRIGENOMICS
MOLECULAR BIOLOGY
The Quest for Integration |
|
The
science of nutrition and genetics has recently become a distinct
discipline embraced by top genetic researchers worldwide.
The triumph of molecular biology and its relation to nutrition
and genetics has become the hope-chest of researchers who
lead the quest to mitigate or control genetic polymorphisms
known to shorten lifespan in humans.
Nutrients and foods can now be safely designed to encode transporters,
receptors, carrier proteins, enzymes and hormones.
|
|
|
For
NutraGenomic scientists, this means that they can begin to construct
a picture of dietary interactions from the level of body composition
and whole-body physiology, from substrate-flux through metabolic
pathways, to the amount and activity of crucial enzymes, and on,
down to the effects of gene expression.
The
science of NutraGenomics focuses on polymorphisms in specific genes
that encode particular receptors or transporters. This research
impacts the development of new methodoligies in treating severe
genetic diseases, such as Sickle Cell.
The
model for nutritional genomics is the work that has already been
done on drug-gene interactions, and the science of nutrition and
genetics, NutraGenomics, has now joined in the search for new physiological
systems that will impact genetic coding.
One
of the major advances in NutraGenomics is the discovery of a new
approach in the treatment of Sickle Cell disease and Thalassemia.
The
scientific team at the Encode Research Project is a virtual
Who’s-Who of physicians and researchers, including the world’s
leading L-Arginine researcher and Patent holder, Dr. Ann de Wees
Allen, along with her team, Clair Francomano, M.D., former Chief
of Medical Genetics Branch at the National Institutes of
Medicine (NIH), National Genome Research Institute,
Chief of Human Genetics for the Laboratory of Genetics at the
National Institute on Aging, and Dr. Randall Maxey, M.D. PhD.,
renowned cardiologist and former President of the National Medical
Association, current Chief of Medicine, Encode Research Foundation
for Ethnic-Related Diseases.
|
|
The
Encode Research Project ® has broken new ground
in the field of genomics, and has, for the first time in the
history of man, found a promising treatment for Sickle Cell
Disease and Thalassemia, the number one genetic disease in
the world.
The Encode
Research Project ® has dedicated full resources,
both scientific and monetary, to develop over the next decade,
breakthrough Encoding Systems encompassing Nutrition and
Genetics.
|
|
Team
Director, Dr. Ann de Wees Allen received the first Glycemic Patent
ever awarded worldwide, and went on to discover that L-Arginine
is a Blind Amino Acid ®, receiving another Patent for L-Arginine
biochemistry, with four Patents-Pending in the field of L-Arginine
research.
With
over 25-years of clinical research as Chief of Biomedical Research
at the Glycemic Research Institute in Washington, D.C.
(Glycemic.com), Dr. Allen conducts Human In Vivo Clinical Trials
for the U.S. Government, as well as the largest food companies in
the world, including Proctor & Gamble and Hershey Foods.
The
goal of the Encode Research team is to “identify and develop
tools that access signal-transduction pathways on a genomic-specific
scale.” Their most recent work focuses on African-American
variants that carry life-altering codes.
According
to the Journal of the American Medical Association (JAMA),
both Sickle Cell Disease and Thalassemia are related to Dysregulated
Arginine Metabolism, which leads to dangerously low levels of serum
L-Arginine, and its metabolite, Nitric Oxide (NO).
The
free form amino acid, L-Arginine, is key in developing methods of
treating Sickle Cell Disease and Thalassemia, which requires “jumping
over” the Sickle Cell trail on human DNA. The Encode Research
Team has broken the bounds of genetic research, discovering the
first process for jumping-over the Sickle Cell & Thalassemia
DNA polymorphism, and has filed Patents on this treatment.
Dr.
Allen has named her genetic breakthrough “TLSV”, which
stands for “The Louis Shapiro Variant”, named
after a colleague of Dr. Allen’s in Washington, D.C., who
believed in her research, and supported her efforts in the field
of L-Arginine research. In 1983, there was virtually no published
research in the field of L-Arginine research, and as a pioneer in
this field, Dr. Allen had to seek research funds from friends and
relatives in order to file Federal patents. That is no longer an
issue, as Dr. Ann de Wees Allen’s patents have now generated
over one $ Billion dollars, were featured on the front page of the
Wall Street Journal, and named Breakthrough Product
of the Year by Success magazine.
|
 |
FUTURE
SCIENCE
Breaking the code to genetic diseases, such as Sickle Cell
and Thalassemia, leads the way to treating and curing global
diseases that are tied to human DNA. In the future, genetic
diseases may be treated by a simple pill, or in the case of
Encode, a cherry drink. These treatments are free
of side effects, and are referred to as “Edible Computer
Chips ®” by the Encode team.
|
|
|
